Possible role of Epoxyeicosatrienoic acid in prevention of oxidative stress mediated neuroinflammation in Parkinson disorders

Navya Lakkappa a, Praveen T. Krishnamurthy a,*, Bruce D. Hammock b, D. Velmurugan c, M.M. Srinivas Bharath d

a Department of Pharmacology, JSS College of Pharmacy (A Constituent College of JSS University, Mysore), Ootacamund, Tamilnadu, India
b Department of Entomology and Nematology, and Comprehensive Cancer Research Center, University of California, Davis, CA, USA
c Department of Crystallography and Biophysics, University of Madras, Guindy Campus, Chennai, India
d Department of Neurochemistry, National Institute of Mental Health & Neuro Sciences, Bangalore, India

A R T I C L E  I N F O

Article history:
Received 22 February 2016
Accepted 4 June 2016

Keywords:
sEH
PD
Neuroprotection
Cytochrome P450
Neuroinflammation
Oxidative stress
Apoptosis

A B S T R A C T

Parkinson’s disease (PD) is a multifactorial neurodegenerative disease involving oxidative stress, neuroinflammation and apoptosis. Epoxyeicosatrienoic acids (EETs) are arachidonic acid metabolites and they play a role in cytoprotection by modulating various cell signaling pathways. This cytoprotective role of EETs is well established in cerebral stroke, cardiac failure, and hypertension, and it is due to their ability to attenuate oxidative stress, endoplasmic reticulum stress, inflammation, caspase activation and apoptosis. The actions of EETs in brain closely parallel the effects which is observed in the peripheral tissues. Since many of these effects could potentially contribute to neuroprotection, EETs are, therefore, one of the potential therapeutic candidates in PD. Therefore, by increasing the half life of endogenous EETs in vivo via inhibition of sEH, its metabolizing enzyme can, therefore, constitutes an important therapeutic strategy in PD.

© 2016 Elsevier Ltd. All rights reserved.

Introduction

Parkinson’s disease (PD) is the second most common progressive neurodegenerative disorder with a characteristic symptoms such as bradykinesia, rigidity, resting tremor and posture instability [1–4]. It is a multifactorial disease involving age, genetic and environmental factors. Aging is associated with mitochondrial dys-function, increased free radical production and oxidative stress, which may lead to genomic instability and DNA mutations, with reduced survival [5–7]. For the past 15 years, genetic characterization of PD has shown sequence or copy number variants in at least six genes [(synuclein alpha (SNCA), leucine-rich repeat kinase 2 (LRRK2), E3 ubiquitin-protein ligase parkin (PARK2), PSEN1, PSEN2, presenilin-1 (PSEN1), presenilin-2 (PSEN2)] which have been identified to cause monogenic forms of PD [7,8]. Environmental factors such as head trauma and exposure to pesticides (rotenone, parquat, dieldrin, etc.), solvents (trichloroethylene, carbon tetrachloride, n-hexane etc.), and metals (lead, iron, manganese etc.) are reported to cause destruction of dopaminergic neurons through oxidative and inflammatory reactions [9]. The morphologic hallmark of PD is the presence of alpha-synuclein (α-syn)-rich Lewy bodies within the dopaminergic neurons, which are mainly formed due to mutations in α-syn gene, leading to protein aggregation. Lewy body formation is observed both in familial and sporadic forms of PD [10–14]. Molecular level analysis of PD confirm that oxidative stress, mitochondrial
dysfunction and neuroinflammation are the major contributing factors [15].

Plasma membrane arachidonic acid (AA) released by phospholipids by phospholipase A2 (PLA2) is metabolized to prostaglandins and thromboxane by cyclooxygenase (COX), to leukotrienes by lipoxygenase (LOX), and to Epoxyeicosatrienoic acid (EETs) by cytochrome P450 (CYP450) oxidases (Fig. 1) [16,17]. Four EETs regioisomers, 5,6-, 8,9-, 11,12-, and 14,15-EET are produced by CYP450 epoxygenases pathway. These regioisomers are quickly metabolized to inactive or less active metabolites by soluble or to a lesser degree the microsomal epoxide hydroxylases (sEH or mEH) and their estimated in vivo half-life is of few seconds to minutes [18] (Figs. 1 and 2). EETs are present in heart, lungs, kidneys, gastro-intestinal tract and in brain [19,20]. Sura et al., reported the preferential expression sEH in neuronal cell bodies, oligodendrocytes, astrocytes, meningeal blood vessels, and in choroid plexus of human brain [20]. EET's are reported to exhibit anti-inflammatory and antioxidant properties which protect against mitochondrial dysfunction and apoptosis and play an important role in regulation of cerebral blood flow [21]. A diverse class of agents such as amides, ureas, thioamides, thioureas, carbamates, acyl hydrazones, chalcone oxides, etc., has been reported to possess sEH inhibitory potential [22]. Some of the sEH inhibitors have been extensively studied for their cytoprotective benefits in hypertension, ischemic heart disease, heart failure, renal-accardiac failure, diabetic neuropathy, cancer and obesity [23–31]. Although EETs are widely distributed in the brain, little research has been carried out to exploit their cytoprotective benefits in the treatment/prevention of PD [25,32].

The hypothesis proposed

The cytoprotective properties of EETs have been well established in various peripheral disorders and they may play a similar role in the brain cells. The cytoprotective effect of EETs, however, is limited by their metabolism via soluble epoxide hydrolase [23,25,33–38]. Therefore, we hypothesize that increasing the half life of endogenous EET's through inhibition of its major metabolizing enzyme, soluble epoxide hydrolase [39], is, therefore a novel approach to prevent/treat the PD [21,40–44].

Justification of proposed hypothesis

The pathogenesis of PD is associated with oxidative stress, mitochondrial dysfunction, protein aggregation, misfolding, inflammation, excitotoxicity, and apoptosis [45]. Oxidative stress results due to overproduction of reactive species or a failure of cell buffering mechanisms that normally limit their accumulation. This oxidative stress results in damage to proteins, lipids, and nucleic acids has been found in the substantia nigra (SN) of PD patients [46]. The ROS production occurs due to a variety of factors including dopamine metabolism, exposure to environmental toxins, mitochondrial dysfunction, probably all of which can result in inhibition of mitochondrial Complex I activity in the SN of PD patients [45–47]. PD patients display impairment of endogenous protective mechanism such as lowered antioxidants such as glutathione, superoxide dismutase, etc. EETs have been reported to promote endogenous mechanisms to buffer free radicals, thereby reducing the oxidative damage to sub-cellular organelles [21,48]. A study by Liu et al. demonstrated that EETs attenuate oxidative stress, mitochondrial dysfunction, caspase activation, and apoptosis in carcinoma cells treated with arsenic trioxide (ATO) [49]. The results showed that pretreatment with 11,12-EET increased the expression of the antioxidant enzymes superoxide dismutase and catalase and inhibited ATO-induced apoptosis and activation p38 mitogen-activated protein kinase, c-Jun NH2-terminal kinase, caspase-3, and caspase-9, which could have potential neuroprotective and therapeutic implications for PD [49]. However the specific signaling mechanisms by which EETs exert their direct protective effects in astrocytes and neurons still remain unclear.

Neuroinflammation secondary to oxidative stress is one of the primary mechanisms involved in PD. Elevated pro-inflammatory cytokines, such as IL-1β, IL-6, and TNF-α have been reported in the SN of PD patients [50]. The accumulation of alpha-synuclein

![Fig. 1. Arachidonic acid pathway in astrocytes, dopaminergic neurons, and cerebral blood vessels. AA – arachidonic acid, COX-2 – cyclooxygenase-2, LOX – lipoxygenase, EET's – Epoxyeicosatrienoic acids, sEH – soluble epoxide hydrolase, CYP2C – cytochrome p450 2C, CYP2J – cytochrome p450 2J, DHETs – dihydroxyeicosatrienoic acids, cPLA – phospholipase A.](image-url)
The anti-inflammatory effects of EETs could also be caused via transient receptor potential vanilloid type 1 (TRPV1), which is activated in brain due to heat, endogenous lipid molecules and oxidative stimuli [55] and also due to exogenous agonists such as evodiamine (an active ingredient of the evodia fruit) and capsaicin (an active ingredient of hot pepper). Activation of TRPV1 permits calcium (Ca^{2+}) entry, which results in an elevated level of intracellular Ca^{2+} which serves as a signal to elicit anti-inflammatory responses in neurons [56,57]. In addition to anti-inflammation, EETs are reported to activate PPAR-γ thereby promoting various physiological processes such as fatty acid and glucose metabolism, angiogenesis, cellular proliferation and differentiation, [58]. The activation of PPAR-γ are reported to suppresses the NF-κB mediated expression of molecules such as VCAM-1, ICAM-1, and endothelins that are involved in the inflammatory response [56]. They also increase the endogenous antioxidant levels of glutathione, SOD, catalase etc. There are several studies which have reported the neuroprotective properties of PPAR-γ agonists in PD [59].

The dopaminergic neurons in the SN of PD patients have reported increased glutamate receptors, and receive glutamatergic innervations from the subthalamic nucleus and cortex. The excessive NMDA receptor activation by glutamate increases intracellular Ca^{2+} levels which in turn activate cell death pathway [60]. The intracellular Ca^{2+} is sequestered regularly into the endoplasmic reticulum and mitochondria to prevent the activation of cell death pathways. Due to increased oxidative stress, mitochondrial dysfunction there is imbalance in Ca^{2+} levels [61]. The Blockade of L-type Cav1.3 calcium channels are reported to decrease the severity of PD. The excitotoxicity of glutamate is reported to be mediated by sustained increase in the cytosolic Ca^{2+} concentration. EETs have been reported to inhibit cardiac L-type calcium channels which play an important role in regulating cardiac contractility.
heart rate etc [62]. Similar mechanisms, may sequester the excessive Ca" overload and Ca" mediated glutamate excitotoxicity in PD [25,37]. Isradipine a L-type calcium channel inhibitor is in the Phase III clinical trial, which has therapeutic potential in slowing the progression of the PD in pre-clinical studies [63]. The role of EETs in the brain and CNS appears to closely parallel the functions as described in other peripheral tissues [21].

Apart from the above proposed mechanisms, the signaling of by EETs is involved in the process that is distinct to CNS functions. EETs modulate neuronal pain processing in the brainstem. The CYP oxidase metabolic pathway interacts with the neuroactive endocannabinoid pathway [48], which plays an important role in regulating neurohormone release from neuroendocrine regions of the brain. The function of EETs in the neurogenic regulation of cerebral blood flow suggests that EETs may be key regulators of synaptic transmission, a function which is distinct to CNS [37]. Strauss et al., evaluated the effect of traumatic brain injury (TBI) on behavioral phenotypes in soluble Epoxide Hydrolase Knockout Mice (Ephx2-KO). They report that the Ephx2-KO mice showed improved motor coordination in beam walk test when compared to wild-type and a minor impairment in working spatial memory independent of TBI in Morris water maze test. The results of this study show that sEH deficiency interacted both with neurologic and cognitive performance, independent of brain injury [64].

Experimental works carried out by Xiaocui Qin et al., on MPTP model of mice and primary cortical neuronal cell cultures, have reported the increased expression of sEH in MPTP-treated mice. The study reported sEH deficiency and inhibition significantly attenuated tyrosine hydroxylase (TH)-positive cell loss and improved rotarod performance in mice. Data suggested that sEH inhibition might be a powerful tool to protect dopaminergic neurons in PD [65]. Terashvili et al., performed mechanistic studies on co-cultures of astrocytes and N27 dopaminergic neuron and reported that EETs (released from astrocytes and neurons) enhanced cell viability against ROS induced injury. Further, sEH inhibitor (12-(3-adamantan-1-yl-ureido)-dodecanoic acid (AUDA) increase the EET levels, thereby increasing the neuronal viability and projecting the cytoprotective ability of EETs against hydrogen peroxide induced oxidative stress in brain [40].

One of the drawbacks associated with EETs is their promitogenic action which may result in uncontrolled cell division and cancer progression. However, Emun Abdu et al., have reported the administration of regioisomeric mixture of EETs resulted in a concentration dependent increase in axon outgrowth in primary sensory and cortical neuronal cell cultures. This suggested a novel therapeutic use of EETs in promoting nerve regeneration [66]. Munzenmaier et al., have proved that the promitogenic actions of EETs resulted in the formation of endothelium tube, when the cerebral microvascular endothelial cells were cocultured with astrocytes [67]. EETs have also been reported to play an important role in promoting angiogenesis in cerebral vasculature which is due to its promitogenic potential [21,36,48,68]. Thus the promitogenic property of EET exhibit positive or negative actions on CNS is still under research.

In peripheral vasculature, sEH inhibitors are reported to exert vasodilatory effects [24], however, in the cardiovascular regions of brain such as brainstem they are reported to increase blood pressure (BP) and heart rate (HR) in spontaneously hypertensive rats but not in Wistar Kyoto rats [69]. Hence the central role of sEH inhibitors in hypertension is not yet clear.

**Conclusion**

Since the pathogenesis in PD is multifactorial, novel compound(s) that simultaneously target multiple degenerative pathways are required. In this regard, our hypothesis on the potential therapeutie effects of EETs is viable since EETs protect against oxidative stress, mitochondrial dysfunction, neuroinflammation and apoptosis. Administration of sEH inhibitors should be tested in various PD models, such as LPS, MPTP, and rotenone. Further, since EETs are naturally occurring endogenous compounds, their elevation might not pose neurotoxicity or systemic toxicity. However, additional experiments are required to understand the solubility of sEH inhibitors, their ability to cross the BBB and bioavailability in the brain. However, it needs to be seen whether such approaches could be tested as independent or adjunct therapy along with existing drug therapy with dopamine replacement.

**Conflict of interest**

**Funding**

This work was partially supported by National Institute of Environmental Health Sciences (NIEMS), United States, (Grant number: ES02710). Bruce D. Hammock is a George and Judy Marcus senior fellow of the American Asthma Foundation.

**Disclosures**

The author declares that there is no conflict of interest.

**References**